Profluent Announces Strategic Partnership with Eli Lilly to Develop AI-Designed Recombinases for Genetic Medicine
XX min read
TL;DR
● Collaboration combines Profluent'sfrontier AI platform with Lilly's leading capabilities in genetic medicines
● AI-designed recombinases aim tounlock kilobase-scale DNA editing capabilities across multiple diseases withsevere unmet needs
Read the full press here release for more.
Oops! Something went wrong while submitting the form.
Share on Social
